MEDARTIS BUYConfirmation of the expanding wedge reversal with partial rise and break out with confirmation of the reversal structure.
Target is the IPO price
BIO
0.3 CHF
619.00 K CHF
212.01 M CHF
12.98 M
About MEDARTIS N
Sector
Industry
CEO
Matthias Schupp
Website
Headquarters
Basel
Founded
1997
ISIN
CH0386200239
FIGI
BBG00K68NZ53
Medartis Holding AG engages in the development, manufacture, and sale of medical devices for surgical fixation of bone fractures. It operates through the following geographical segments: EMEA, US, APAC, and LATAM. The company was founded by Thomas Straumann on November 3, 1997 and is headquartered in Basel, Switzerland.
LET INSPIRE FROM SPECULATIVE MOUVEMENTJust looked at IPO in switzerland this year. After a speedy scroll I was captured by two projects. Medartis and Sensirion.
Sensirion just mooned and if I had a little more time for stock market it was a clear buy for me.
Now let analyse Medartis.
IPO are tricky. There are differents movement aft
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MED is 52.2 CHF — it has increased by 0.38% in the past 24 hours. Watch MEDARTIS N stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange MEDARTIS N stocks are traded under the ticker MED.
MED stock has fallen by −5.61% compared to the previous week, the month change is a −5.26% fall, over the last year MEDARTIS N has showed a −29.84% decrease.
We've gathered analysts' opinions on MEDARTIS N future price: according to them, MED price has a max estimate of 110.00 CHF and a min estimate of 85.00 CHF. Watch MED chart and read a more detailed MEDARTIS N stock forecast: see what analysts think of MEDARTIS N and suggest that you do with its stocks.
MED stock is 5.56% volatile and has beta coefficient of 0.94. Track MEDARTIS N stock price on the chart and check out the list of the most volatile stocks — is MEDARTIS N there?
Today MEDARTIS N has the market capitalization of 709.68 M, it has decreased by −1.55% over the last week.
Yes, you can track MEDARTIS N financials in yearly and quarterly reports right on TradingView.
MEDARTIS N revenue for the last half-year amounts to 111.50 M CHF, despite the estimated figure of 114.25 M CHF. In the next half-year revenue is expected to reach 120.95 M CHF.
MED net income for the last half-year is 2.56 M CHF, while the previous report showed 1.47 M CHF of net income which accounts for 74.84% change. Track more MEDARTIS N financial stats to get the full picture.
No, MED doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 876.00 employees. See our rating of the largest employees — is MEDARTIS N on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDARTIS N EBITDA is 25.93 M CHF, and current EBITDA margin is 15.30%. See more stats in MEDARTIS N financial statements.
Like other stocks, MED shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDARTIS N stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDARTIS N technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDARTIS N stock shows the sell signal. See more of MEDARTIS N technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.